OA11010A - Quinoline derivatives - Google Patents

Quinoline derivatives Download PDF

Info

Publication number
OA11010A
OA11010A OA9800061A OA9800061A OA11010A OA 11010 A OA11010 A OA 11010A OA 9800061 A OA9800061 A OA 9800061A OA 9800061 A OA9800061 A OA 9800061A OA 11010 A OA11010 A OA 11010A
Authority
OA
OAPI
Prior art keywords
compound
formula
alkyl
group
mmol
Prior art date
Application number
OA9800061A
Other languages
English (en)
Inventor
Giuseppe Amaldo Maria
Mario Grugni
Luca Francesco Raeglia
Carlo Farina
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI952461 external-priority patent/IT1276170B1/it
Priority claimed from IT96MI001689 external-priority patent/IT1307331B1/it
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of OA11010A publication Critical patent/OA11010A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA9800061A 1995-11-24 1998-05-22 Quinoline derivatives OA11010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI952461 IT1276170B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
IT96MI001689 IT1307331B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici

Publications (1)

Publication Number Publication Date
OA11010A true OA11010A (en) 2003-03-06

Family

ID=26331326

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800061A OA11010A (en) 1995-11-24 1998-05-22 Quinoline derivatives

Country Status (26)

Country Link
US (1) US6277862B1 (fr)
EP (1) EP0876347B1 (fr)
JP (1) JP2000501104A (fr)
KR (1) KR19990071597A (fr)
CN (1) CN1207730A (fr)
AP (1) AP9801237A0 (fr)
AR (1) AR004972A1 (fr)
AT (1) ATE289994T1 (fr)
BG (1) BG102558A (fr)
BR (1) BR9611820A (fr)
CA (1) CA2238298A1 (fr)
CZ (1) CZ157998A3 (fr)
DE (1) DE69634416T2 (fr)
EA (1) EA002124B1 (fr)
ES (1) ES2236757T3 (fr)
IL (1) IL124522A0 (fr)
MX (1) MX9804107A (fr)
NO (1) NO311212B1 (fr)
NZ (1) NZ323387A (fr)
OA (1) OA11010A (fr)
PL (1) PL326967A1 (fr)
SK (1) SK66798A3 (fr)
TR (1) TR199800924T2 (fr)
TW (1) TW353066B (fr)
UY (1) UY24733A1 (fr)
WO (1) WO1997021680A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290470B6 (cs) 1991-10-18 2002-07-17 Monsanto Technology Llc 5 či 6 členné aromáty jako fungicidy pro kontrolu stéblolamu rostlin, způsob kontroly a fungicidní směs k provedení tohoto způsobu
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) * 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
DE60004654T2 (de) 1999-03-29 2004-06-24 Neurogen Corp., Branford 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
AU4802500A (en) * 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
EP1385839B1 (fr) * 2001-04-11 2006-02-22 GlaxoSmithKline S.p.A. Derives de 3-substitue quinoline-4-carboxamide utilises comme antagonistes du recepteur nk3 et du recepteur nk2
WO2002089802A2 (fr) * 2001-05-08 2002-11-14 Schering Corporation Utilisation d'antagonistes de recepteur de neurokinine pour le traitement de maladies liees aux androgenes
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0303086D0 (en) * 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
RU2007119427A (ru) * 2004-11-09 2008-12-20 СмитКлайн Бичем Корпорейшн (US) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504641A (ja) * 2005-08-11 2009-02-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体の調節剤としてのアルキルピリジルキノリン
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR20100075568A (ko) * 2007-09-28 2010-07-02 글락소스미스클라인 엘엘씨 글리코겐 포스포릴라아제 억제제 화합물 및 이의 약제 조성물
WO2009045830A1 (fr) * 2007-09-28 2009-04-09 Smithkline Beecham Corporation Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
JP5502106B2 (ja) 2008-12-31 2014-05-28 アーデリクス，インコーポレーテッド 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2880338A1 (fr) 2012-08-21 2014-02-27 Ardelyx, Inc. Composes et procedes d'inhibition d'un antiport a mediation par nhe dans le traitement de troubles associes a une retention de fluide ou a une surcharge de sel et de troubles du tractus gastro-intestinal
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2909169A1 (fr) 2013-04-12 2014-10-16 Ardelyx, Inc. Composes de liaison a nhe3 et procedes d'inhibition du transport de phosphate
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2017072629A1 (fr) 2015-10-29 2017-05-04 Cadila Healthcare Limited Combinaison pharmaceutique d'antagoniste du récepteur nk3 et de biguanides
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
UA126283C2 (uk) 2017-01-09 2022-09-14 Арделікс, Інк. Сполуки, придатні для лікування розладів шлунково-кишкового тракту

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPS63119455A (ja) * 1986-06-27 1988-05-24 Nippon Shinyaku Co Ltd グリシン誘導体
PL186665B1 (pl) * 1994-05-27 2004-02-27 Smithkline Beecham Spa Pochodne chinoliny jako antagoniści receptorów NKtachykininy, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca pochodne chinoliny oraz ich zastosowanie
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
WO1997021680A1 (fr) 1997-06-19
EA002124B1 (ru) 2001-12-24
AP9801237A0 (en) 1998-06-30
US6277862B1 (en) 2001-08-21
UY24733A1 (es) 2001-08-27
MX9804107A (es) 1998-09-30
CZ157998A3 (cs) 1998-12-16
KR19990071597A (ko) 1999-09-27
ES2236757T3 (es) 2005-07-16
IL124522A0 (en) 1998-12-06
NO982331L (no) 1998-07-22
DE69634416D1 (de) 2005-04-07
DE69634416T2 (de) 2005-12-29
AR004972A1 (es) 1999-04-07
SK66798A3 (en) 1999-01-11
TW353066B (en) 1999-02-21
PL326967A1 (en) 1998-11-09
JP2000501104A (ja) 2000-02-02
BG102558A (bg) 1999-03-31
EP0876347B1 (fr) 2005-03-02
EA199800477A1 (ru) 1998-12-24
NO311212B1 (no) 2001-10-29
EP0876347A1 (fr) 1998-11-11
TR199800924T2 (xx) 1998-08-21
CN1207730A (zh) 1999-02-10
NZ323387A (en) 2000-02-28
CA2238298A1 (fr) 1997-06-19
NO982331D0 (no) 1998-05-22
ATE289994T1 (de) 2005-03-15
BR9611820A (pt) 1999-07-13

Similar Documents

Publication Publication Date Title
OA11010A (en) Quinoline derivatives
WO1997021680A9 (fr) Derives de quinoline
US6743804B2 (en) Quinoline derivatives as NK3 antagonists
EP0804419B1 (fr) Derives de quinoline utilises comme antagonistes du recepteur nk 3 de la tachykinine
US20020068827A1 (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists
WO1996002509A1 (fr) Derives de quinoline utilises comme antagonistes de la neurokinine 3 (nk3)
EP1377555B1 (fr) Un derive de dioxino[2,3-g]quinoline-9-acide carboxylique en tant qu'antagoniste du recepteur nk3
EP0983262B1 (fr) Derives de quinoline-4-carboxamide comme antagonistes des recepteurs nk-2 et nk-3
EP1131294B1 (fr) Derives de quinoline utilises comme ligands des recepteurs nk-2 et nk-3
AU1031797A (en) Quinoline derivatives
AU757836B2 (en) Quinoline derivatives
US20030004183A1 (en) Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
NZ500371A (en) NK-2/NK-3 antagonists and their use in treating respiratory disease
AU4263200A (en) Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3)- and neurokinin 2 (NK-2) receptor antagonists
CZ416199A3 (cs) Chinolin-4-karboxamidové deriváty jako antagonisté receptoru pro NK-2 a NK-3
KR20010012823A (ko) Ｎｋ-2 및 ｎｋ-3 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체